Lataa...

Pharmacological and protein profiling suggest venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia

PURPOSE: Bruton’s tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase domain. Though ibrutinib results in impressive clinical activity in chronic lymphocytic leukemia (CLL), most patients achieve only partial r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Cervantes-Gomez, Fabiola, Lamothe, Betty, Woyach, Jennifer A., Wierda, William G., Keating, Michael J., Balakrishnan, Kumudha, Gandhi, Varsha
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4537801/
https://ncbi.nlm.nih.gov/pubmed/25829398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2809
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!